漢康生技 - HanchorBio - 創新、卓越、高效

创新驱动生命希望照亮未來

Innovating for Life, Inspiring Hope

Our Possibility

我们的可能性

研发项目

                                                                8
                                +
                            

专利申请

                                                                100
                                +
                            

进入临床IND阶段

最快

                                                                2.3
                                年
                            

2024年的研发投入金额

                                                                7.89
                                亿新台币
                            

FBDB™

技术平台的核心优势

结合先天性与适应性免疫系统多通路协同攻击肿瘤细胞
阻断SIRPα / CD47 信号通路
阻断PD-1 / PD-L1 信号通路
改善肿瘤微环境并进一步激活巨噬细胞/T细胞

更多核心技术

News

最新消息

汉康生技将于ASCO消化道肿瘤大会2026 发布 HCB101 联合标准治疗在第二线胃癌中的早期临床结果

汉康生技将于ASCO消化道肿瘤大会2026 发布 HCB101 联合标准治疗在第二线胃癌中的早期临床结果剂量 […]

1 月 05, 2026

汉康生技 2025 年度里程碑总回顾

汉康生技 2025 年度里程碑总回顾汉康为癌症及自身免疫疾病患者，打造具临床突破力的创新抗癌生物药。汉康生 […]

12 月 29, 2025

HCB101-Shows-Clean- Cytopenia-Sparing-Safety

HanchorBio Announces Oral Presentation of HCB101 at the ESMO Immuno-Oncology Congress 2025

HanchorBio Announces Oral Presentation of HCB101 at the […]

12 月 12, 2025

HANCHORBIO INC. ANNOUNCES CLOSING OF SERIES-A FINANCING

August 5th, 2022 – HanchorBio Inc. (“HanchorBio”), a biotechnology company pioneering the development of next-generation immunotherapies, today announced the successful completion of approximately US$20 million Series-A financing. The proceeds will enable HanchorBio to further expand and accelerate its growing pipeline of the proprietary Fc-based designer biologics (FBDB™) and to support the anticipated investigational new drug (IND)-enabling good laboratory practice (GLP) toxicology studies, IND submissions, and the first part of phase 1 clinical trials.

8 月 25, 2022